Caris Upgrades Par Pharmaceutical (PRX) to Above Average
More News related to PRX
- Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
- Bioalliance Pharma Submits Loramyc(R) NDA to US FDA And Announces a General Shareholders' Meeting to Amend Its By-Laws
- Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
- SOHM Inc.: Rated 'Speculative Buy,' Target Price $0.33 by Beacon Equity Research
- MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
Caris & Co. upgrades Par Pharmaceutical (NYSE: PRX) from Average to Above Average.
Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.
Related Categories
UpgradesStocks Mentioned
+9.60Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
